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The assessment of risk for acute and/or
chronic inhalation oflow-level environmen-
tal air pollutants is complex. Typically, the
database for risk assessment arises from three
separate investigational approaches: epidemi-
ology, animal toxicology, and human inhala-
tion studies. Carefully controlled quantitative
studies ofexposed humans utilize laboratory
atmospheric conditions, considered relevant
to outdoor pollutant levels, or concentrated
particles from the ambient air, and document
health-related effects that result from breath-
ing the atmosphere. Advantage is taken ofthe
highly controlled environment to identify
responses to individual pollutants and charac-
terize exposure-response relationships. In
addition, the controlled environment pro-
vides an opportunity to study interaction
among pollutants per se or with other vari-
ables such as exercise, humidity, or tempera-
ture. Insofar as individuals with acute and
chronic cardiopulmonary diseases can partic-
ipate in exposure protocols, potentially sus-
ceptible populations can be studied.
However, controlled human exposures have
important limitations: for practical and ethi-
cal reasons, studies are limited to small
groups, presumably representative oflarger
populations, to short durations ofexposure,
and to pollutant concentrations expected to
produce only mild and transient responses.
Furthermore, efforts to predict chronic
health effects from acute transient responses
in clinical studies lackvalidation.
In this article we examine the exposure
methodologies and study design issues essential
for performance ofcontrolled clinical studies.
Subsequently, we focus on the investigative
tools available to evaluate respiratory, cardio-
vascular, and pharmacokinetic outcomes.
Finally, our current understanding of
responses ofsusceptible populations as deter-
mined bytheclinical studyis reviewed.
Experimental Design
and Methods
Controlled human exposure studies ofinhaled
gases and particles, especially those designed
to evaluate short-term effects ofairborne pol-
lutants, have been performed in multiple labo-
ratories over the past decade. The major
unique feature ofthe dinical study is the abil-
ity to select, control, and quantify pollutant
exposures ofsubjects ofknown clinical status
and determine their effects on cardiopul-
monary performance under ideal conditions
forconductingphysiologic evaluations.
Typically, modern clinical studies use
exposures to single pollutants or simple pollu-
tant mixtures, exposure durations of
0.5-8 hr, and a double-blind, crossover
design. Exposures are often conducted in
environmentally controlled chambers (25-75
m3 volume) with a single passage ofthe pol-
lutant(s). Physiologic responses may include
lung function, or cardiac rate, rhythm, and
variability. Techniques used to detect poten-
tial biomarkers include bronchoscopy, nasal
lavage, or sputum induction. Techniques are
also available to measure airway size and
mucociliary clearance rates using aerosol
probes and radiolabeled aerosol techniques.
An additional approach is the use of nasal
masks or mouthpiece exposures ofindividual
subjects in place of an exposure chamber.
These design features affect and often deter-
mine the technologic and methodologic
approaches used for pollutant-generated
monitoring and quantitativesampling (1).
There is a major difference with regard to
pollutant generation requirements between
studies utilizing facemask or mouthpiece
exposures and those conducted in relatively
large environmental chambers. With the
mouthpiece, a pollutant-air mixture must be
produced that only slightly exceeds the indi-
vidual subject's respiratory intake require-
ments, e.g., from 5 L min-1 to 50 L min-1
with exercise. In contrast, for chambers oper-
ating with a single pass (no recirculation), 5
to 25 m3 min-1 is the likely flow rate require-
ment, i.e., as much as 1,000 times greater.
Usually the exposure duration required for
this greater generation capacity is also longer
with chamber studies than with mouthpiece
or facemaskstudies.
Monitoring devices are used to determine
whether exposure levels in the breathing zone
are stable or changing. Ideally, monitors are
real-time devices calibrated to indicate con-
tinuously the absolute pollutant concentra-
tions. This level of performance can be
achieved with certain pollutant analyzers such
as for ozone (03), but often the investigator
is provided only qualitative information by
monitors. In this situation, if quantitative
measurements ofpollutant levels are required,
complementary analytical devices must be
used that often are not real-time and only
seriallysample the exposure conditions.
The controlled clinical study provides the
opportunity to examine both healthy volun-
teers and individuals with underlying cardio-
pulmonary diseases. Subjects typically are
classified by age, gender, race, lung function,
and cardiovascular status. Normal volunteers
are characterized by the absence ofallergies,
often documented by skin testing, the lack of
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hyperresponsive airways assessed by inhalation
challenge tests, and absence ofhypertension or
cardiac arrhythmias. Subgroups ofhealthy
volunteers may include adolescents, elderly
subjects, and smokers. Healthy volunteers
typically are able to perform vigorous exercise
forextended periods.
Exercise performed either on a treadmill
or bicycle is an important component ofthe
exposure study. Exercise enhances the pollu-
tant dose both by increasing ventilation and
by causing a switch from nasal to oral
breathing, effectively bypassing the nose.
The nose may remove some particles and
gases, variably reducing their delivery to the
lower respiratory tract (2). In addition, the
effect of exercise on airway drying may
enhance the response to pollutants.
Finally, because dinical studies often use
small numbers ofvolunteers, it is essential
that sample size calculations be performed to
make certain the study has adequate power.
This is often an important limitation in con-
trolled human exposures. Statistical issues in
controlled clinical study designs have been
consideredbyVan Ryzin (3).
Assessing Responses
in Human Studies
The choice of outcomes to be assessed in
human clinical studies can be guided by both
scientific and practical considerations.
Clearly, the outcomes of interest depend on
what is known and expected about the effects
ofthe pollutant being studied. Results from
epidemiologic investigations, occupational or
accidental exposures, or animal exposure
studies may suggest the range ofeffects ofa
given agent. The chemical behavior of the
agent may predict its effects. For example,
SO2 is a reactive and soluble gas and therefore
exerts its effects predominantly in the upper
airways and major bronchi where it is com-
pletely absorbed. 03, although very reactive,
is relatively insoluble. Because it is not
entirely dissolved in the epithelial lining fluid
ofthe upper airway, it persists in the inhaled
air, even to the alveolar space. Thus, effects
are expected and found throughout the respi-
ratory tract. In contrast to these irritant gases,
carbon monoxide passes into the blood with
virtually no pulmonary toxicity; its health
effects result from binding to hemoglobin
and resulting tissue hypoxia.
Practical considerations obviously guide
and limit outcome measures in human dini-
cal studies. For safety and comfort reasons,
human studies utilize exposure protocols and
pollutants designed to elicit transient, clini-
cally insignificant effects in relatively healthy
subjects, using minimally invasive measure-
ment techniques. The usefulness ofhuman
studies has been extended with the develop-
ment oftechniques for safely sampling cells
of the lower airway and by the ongoing
search for markers ofpollutant effects. This
section reviews traditional and more recent
outcome measures used in human clinical
studies ofairpollution.
RespiratoryResponses
Virtually every clinical test designed to assess
the presence or severity ofrespiratory disease
has been used to measure the effects of
inhaled pollutants in either clinical or epi-
demiologic studies. The use of traditional
tests oflung mechanics in human clinical
studies has been reviewed (4), and is dis-
cussed only briefly; emphasis instead is placed
on more recently developed methods for
assessing respiratory responses.
Pulmonaryfunction tests. Despite the
development ofnewer and more direct mea-
sures ofpollutant effects on the airways, sim-
ple spirometry remains a mainstay in human
clinical studies. The measurement techniques,
equipment, and interpretation have been
reviewed extensively (5). The most com-
monly evaluated parameters obtained from
spirometry are the forced vital capacity
(FVC), forced expiratory volume in 1 sec
(FEV1), and the maximal flow-volume curve.
During the past 10 years, the vast majority of
human pollutant exposure studies have evalu-
ated responses with at least one ofthese para-
meters. The reasons for selecting these tests
are obvious. They are simple to perform, and
the results are reproducible within subjects.
Standards for spirometry have been estab-
lished by the American Thoracic Society (6),
and ranges ofnormal values have been estab-
lished (4). Results oftesting, especially FEV1,
have been found to correlate well with func-
tional status. For example, in one study in
healthy subjects and in patients with chronic
bronchitis, a reduction in FEV1 ofmore than
5% in the healthy subjects and ofmore than
15% in patients with airflow limitation was
required to be considered significant (8).
One potentially confounding problem
with spirometry is that the test itselfmay alter
the parameters being tested. For example, the
deep inspiration that precedes measurements
of forced expiratory flow causes transient
bronchodilation and reduces induced
bronchoconstriction in the healthy individual
but may cause bronchoconstriction in the
asthmatic. Performance ofspirometry also
appears to increase the airway production of
nitric oxide (9, a measurement used in some
studies to assess airway inflammation non-
invasively. These changes should be consid-
ered in designing and interpreting the results
ofclinical studies.
Other tests of pulmonary mechanics
indude the measurement ofairway resistance
or its reciprocal, conductance, analysis of
partial flow-volume loops and flow rates at
specific lung volumes, and closing volumes.
Airway resistance testing is influenced by
changes in the major bronchi and upper air-
way, including the larynx. Partial volume
flow rates and closing volumes were designed
to provide more sensitive measures with
greater sensitivity for small changes, particu-
larly in the more distal airways (10).
Weinmann et al. (11) have used partial vol-
ume flow rates to indicate possible delayed
small airway effects following 03 exposure.
Although these and other techniques may
prove more sensitive than FEV1 for detecting
mild obstruction or peripheral airway
changes, the methods often lack reproducibil-
ity and there is uncertainty regarding their
interpretation.
Airway responsiveness. The testing of
nonspecific airway hyperresponsiveness has
proven useful for assessing airway responses to
low concentrations ofenvironmental airway
pollutants. These tests measure responses to
inhalation of pharmacologic broncho-
constricting agents such as methacholine, car-
bachol, or histamine. Other stimuli of
bronchoconstriction used in clinical studies
include isocapnic cold air hyperventilation
and inhalation ofincreasing concentrations of
SO2. Responses are measured with the usual
pulmonary function measures, typically FEV1
or airways resistance. Increasing concentra-
tions of a bronchoconstricting agent are
inhaled to construct a dose-response curve,
and the results areexpressed as the provocative
concentration (PC) necessary to produce a
given change in function, such as a decrease in
FEV, of20% (PC20). The PC20 is obtained
from the log-dose-response curve by linear
interpolation ofthe last two points; the lower
the PC20, the greater the responsiveness.
Asthma is characterized by a significant
increase in nonspecific airways hyper-
responsiveness compared with that in healthy
subjects. Studies of subjects with asthma
therefore need to use considerably lower ini-
tial concentrations ofthe bronchoconstricting
agent. Furthermore, airway diameter influ-
ences the results of challenge testing. For
example, an airway already constricted to
50% of its baseline diameter needs a much
smaller concentration of methacholine to
achieve a further 20% reduction. Thus, the
results of challenge testing are difficult to
interpret ifbronchoconstriction is already
present at the time oftesting.
Airway challenge studies have been used
to assess the effects ofpollutant exposure on
airway responsiveness and to determine
whether baseline levels ofresponsiveness pre-
dict lung function decrements in response to
pollutant exposure. For example, subjects
with mild asthma demonstrated increased air-
way responsiveness following exposure to
NO2 (12) or sulfuric acid aerosol (13).
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Healthy subjects experienced increased
responsiveness to carbachol following 6-hr
exposures to 2.0 ppm NO2, in the absence of
changes in lung function (14). Utell et al.
(15) found a relationship between baseline
airways responsiveness assessed by carbachol
in asthmatic subjects and responsiveness to an
inhaled sulfuric acid aerosol. In contrast, air-
ways responsiveness to methacholine was not
predictive ofthe FEV, decrement in response
to 03 exposure in either smokers or
nonsmokers (16).
Fiberoptic bronchoscopy. Development of
fiberoptic bronchoscopy in the 1970s revolu-
tionized the diagnostic evaluation ofpatients
with pulmonary disease, and this technique is
now widely used to sample the respiratory
tract for research purposes. Its use in studies
of asthma has been reviewed recently (17).
Bronchoscopy was first used by Seltzer and
colleagues (18) to detect airway inflammation
in response to 03 exposure. Since then, bron-
choscopy has allowed investigators to charac-
terize the nature ofthe airway inflammatory
response to single and repeated exposures to
03 in healthy, allergic, and asthmatic subjects
(19-22). It has been used to study the effects
ofexposure to many pollutants in addition to
03, including NO2 (23-25), SO2, (26), acid
aerosols (27-29), and diesel exhaust (30).
A growing number of techniques have
been developed using the access provided by
the fiberoptic bronchoscope to sample fluids
and cells of the lower airway (Table 1).
Bronchoalveolar lavage (BAL), the serial
installation and removal offluid through a
bronchoscope wedged in a distal airway, has
provided an opportunity to sample the
epithelial lining fluid and cells of the distal
airways. Evidence suggests that cells recov-
ered by BAL reflect those present in the pul-
monary parenchyma in disease states such as
sarcoidosis and idiopathic pulmonary fibrosis
(31). However, cells from the pulmonary
interstitium, some ofwhich may have a key
role in the pulmonary immune response
(32), are notsampled using this technique. A
modification ofthe original technique ofser-
ial instillation ofaliquots ofsaline involves
separate analysis ofthe first returned portion
offluid, which preferentially samples the dis-
tal conducting airways in which the bron-
choscope is wedged. Fluid obtained from
subsequent aliquots more closely reflects
alveolar sampling (33). This concept of
regional lavage was extended with the use of
proximal airway lavage (34), in which a
catheter with two inflatable balloons and a
port between them is inserted through the
bronchoscope into a mainstem bronchus.
The balloons are inflated to isolate the
bronchus, and repeated small-volume washes
are performed using the port between the
balloons. Care must be taken during the pro-
cedure to avoid prolonged balloon inflation,
as some subjects may experience significantly
decreased arterial oxygen tension during
occlusion of the airway. The technique has
been used successfully in both healthy volun-
teers and subjects with mild asthma (35). A
modification ofthis technique has been used
to study the effects of03 exposure in healthy
and asthmatic subjects (36). However, this
technique is not often used because of its
increased complexity and variability as well
as difficulty in interpreting the findings.
The fiberoptic bronchoscope has been
used to instill particles into a single sub-
segmental airway in human subjects to exam-
ine localized epithelial responses in an isolated
lung region (36). The exposed segment is
then sampled subsequently using BAL and/or
biopsy. This approach is similar to segmental
allergen challenge in studies of the patho-
physiology ofasthma. It permits the delivery
ofrelatively high concentrations ofparticles
directly into the airway without the potential
risks involvedwith inhalation exposures.
Epithelial cells and tissue can also be
obtained through the bronchoscope using
brushes or biopsy forceps, respectively.
Endobronchial biopsies have been shown to
be safe in healthy volunteers and subjects
with mild or moderate asthma. Although
bleeding can occur at the site ofa biopsy, it is
almost never clinically significant. The tissue
samples are small, but sufficient material can
be obtained to examine cellular patterns of
gene expression using immunologic staining
and in situ hybridization. In studies utilizing
pollutant and control exposures, with each
subject serving as his/her own control, it is
important to avoid carryover effects, in which
mucosal repair processes may influence the
results ofthe second study. The combination
of pollutant exposure and endobronchial
biopsies may induce subtle changes in airway
cytokine expression that persist as much as
threeweeks after exposure (37).
Endobronchial biopsy should not be
confused with transbronchial biopsy, a proce-
dure designed to obtain alveolar tissue from
the human lung for clinical diagnostic pur-
poses. The biopsy forceps are advanced into
Table 1. Bronchoscopic procedures used in clinical studies.
Procedure Description
BAL Bronchoscope wedged in a distal airway;
sequential instillation and recovery of sterile saline
Bronchial lavage Separate analysis offirst recovered aliquot of
BAL(see above)
Proximal airway Double-balloon occlusion catheter placed in a
lavage main bronchus; lavage performed via port
between occluding balloons
Bronchial brush Passage of small brush through suction port,
biopsy brush airway surface
Endobronchial Passage oftiny alligatorforceps through
biopsy suction port; obtain 1-2-mm tissue sample
from bronchial epithelium
Transbronchial Passage oftinyalligatorforceps through
biopsy the bronchial wall; obtain small samples of
alveolartissue
Bronchial Agent( allergen, particles) instilled via suction
instillation channel ofbronchoscope; sampling with BAL,
biopsy
Purpose and advantage
Samples distal airwayand alveolar space,
with recovery of epithelial lining fluid,
surfactant components, and cells;
relatively reproducible findings
Preferentially samples distal conducting
airways in comparison with subsequently
recovered aliquots
Samples large conducting airway separate
from alveolar space and distalairways
Samples ofairway epithelial cells; cells
can be cultured and passaged
Samples epithelium insitu; provides
tissue for histology, immuno-
cytochemistry, in situhybridization
Samples alveolartissue and distal
bronchial epithelium
Most useful for studies ofairwaycellular
responses in vivo; allows safe study of
high tissue doses
Disadvantages
Protocols differamong labs; serial
measurements not possible; findings
may not reflecttissue effects
Sample is ofmixed bronchial and
alveolar origin; protocols differ
among labs
Relatively invasive; difficult to
perform; may causetransient
hypoxemia
Lowviabilityand limited number
of recovered cells
Limited to majorconducting airways;
small tissue samples; relatively
invasive; bleeding can occur
(rarelysignificant)
Small tissue samples; invasive;
Potential complications include
pneumothorax, hemorrhage
Effects of instillation maydiffer
from inhalation; difficult to control
dose
Environmental Health Perspectives * Vol 108, Supplement 4 * August 2000 607UTELLAND FRAMPTON
the most distal airways and samples obtained
either blindly or under fluoroscopic guidance.
This procedure may be complicated bypneu-
mothorax and rarely, lung hemorrhage, and
has not been used in clinical studies ofair
pollution. Recent studies have utilized trans-
bronchial biopsy to demonstrate the presence
of inflammation at the alveolar level in
subjects with nocturnal asthma (38).
Sputum induction. In recent years,
sputum induction has emerged as a research
tool forsampling the cells and epithelial lining
fluid ofthe lower respiratory tract in humans
(39,40). Sputum can be reliably induced in
asthmatic subjects as well as in most healthy
subjects using nebulized 3-5% saline. The
cells recovered are representative ofthe lower
airways and provide a measure of airway
inflammation. Asthmatic subjects have more
eosinophils and polymorphonuclear leuko-
cytes (PMNs) in sputum than healthy sub-
jects. Sputum inflammatory cells increased
with asthma exacerbations (41.42) and aller-
gen challenge (43), and decreased with pred-
nisone therapy (44). The results appear to be
qualitatively similar to findings in the first
(bronchial) aliquotofBALfluid (45).
The process ofsputum induction itself
appears to induce amild airway inflammatory
response. For example, when two inductions
are performed 24 hr apart, the second induc-
tion has a higher recovery ofPMNs (46,47).
Thus, caution must be used in designing
studies with serial measurements. Sputum
induction is well tolerated, even in those with
severe asthma, but some asthmatic subjects
experience bronchoconstriction in response to
the nebulized saline. Pretreatment with bron-
chodilators is effective in preventing the
aerosol-induced bronchoconstriction.
Some subjects are unable to produce
sputum following induction. Approximately
two-thirds ofhealthy subjects, and more than
90% of asthmatic subjects, are able to be
induced. Individuals able to produce sputum
do so on subsequent challenges and the find-
ings on repeat sputum inductions are quite
consistent (r= 0.80) among individuals (48).
Fahy et al. (49) demonstrated that sputum
induction detects airway inflammation fol-
lowing exposure to 0.4 ppm 03 for 2 hr in
healthy subjects. In contrast, exposure to 0.3
ppm NO2 for 1 hr, with moderate intermit-
tent exercise, did not alter cell recovery in
induced sputum in subjects with mild asthma
or chronic obstructive pulmonary disease
(COPD) (50). These findings are consistent
with findings in BAL fluid following expo-
sures to 03 and to NO2. Sputum induction
therefore holds promise as a noninvasive
method for assessing airway inflammation in
dinical andfieldstudies.
Markers in exhaled air. Biochemical
processes at the epithelial level may release
gaseous products, some of which can be
detected in the exhaled breath. Investigators
have sampled exhaled air for a variety ofsub-
stances as markers ofeither airway inflamma-
tion or injury, including hydrogen peroxide
(51), CO (52, isoprene (53), ethane (54), and
pentane (55). The technology has been devel-
oped to measure concentrations ofover 100
volatile chemicals in the exhaled breath, with
potential applications in field studies ofenvi-
ronmental exposures (56). Foster et al. (53)
found small but significant increases in exhaled
isoprene levels in healthy subjects following
exposureto03at0.15-0.35 ppm for 130 min.
Measurements of exhaled nitric oxide
have attracted wide interest as a means of
detecting lunginflammation (57). NO is pro-
duced from the action ofnitric oxide synthase
(NOS) on L-arginine. A variety of cells
express one or more ofthe three isoforms of
NOS, including airway epithelial cells and
endothelial cells. Concentrations ofNO are
increased in the exhaled air ofpeople with
asthma compared with healthy subjects (58).
Mild asthmatics not requiring inhaled or oral
corticosteroids have exhaled NO levels 7-fold
greater than normal subjects (59). NO levels
increase further with clinical exacerbations,
correlate with the degree ofairway hyperre-
sponsiveness in steroid-naive asthmatics (60),
and decrease following therapy with corticos-
teroids (61,62). A preliminary report (63)
indicates that exhaled NO is increased in
healthy subjects following exposure to 0.25
ppm 03 2 hr daily for 3 days, suggesting NO
may prove to be a useful marker ofpollutant-
induced inflammation. However, the high
concentrations ofNO found in the pharynx
and nasal passages can confound the measure-
ment of NO production by the lower air-
ways. Furthermore, the lungs have averyhigh
diffusing capacity for NO, and most studies
have not taken into account the removal of
NO from the airways bycapillary blood (64).
The measurements ofgases and volatile
organic molecules in exhaled airshow promise
as noninvasive markers ofpollutant effects,
but considerable work remains to understand
thesignificance oftheobservedchanges.
CardovasculrRe"ponses
Until recently, concern about possible cardio-
vascular effects ofexposure to air pollution
was limited almost exclusively to CO because
ofthe known detrimental effects ofCO on
oxygen delivery. Few studies have assessed
cardiovascular effects ofother pollutants. In
1985 Linn and co-workers (65) found small
reductions in systemic blood pressure in
healthy subjects exposed to NO2, but the
findinghas not been confirmed in subsequent
studies. Drechlser-Parks (66) used a non-
invasive impedance cardiographic method to
estimate changes in cardiac output following
2-hr exposures ofhealthy subjects to 0.60
ppm NO2, 0.4 ppm 03, and a combination
ofNO2 and 03. Compared with air expo-
sure, cardiac output was reduced following
exposure to the combination ofNO2 and 03,
but not for the individual pollutants.
Changes in blood pressure were not reported.
Gong and co-workers (67) performed per-
haps the most definitive study of cardiac
effects of03 exposure. Men with and with-
out stable hypertension underwent arterial
and right heart catheterization, and then per-
formed intermittent exercise in 0.3 ppm 03
for 3 hr. No differences from airexposurewere
seen for avarietyofindices ofcardiac function.
However, heart rate, the rate-pressure product
(an index of left-ventricle work), and the
alveolar-arterial gradient in oxygen tension all
showed greater increases following 03 but
not air exposure. This combination ofeffects
could be clinically important in individuals
with critical coronarylesions.
Epidemiologic studies ofambient partides
have shown a surprisingly robust association
with cardiovascular events, but no mecha-
nism has been found to explain the relation-
ship. Proposed hypotheses explaining cardiac
effects of inhaled particles have included
hypoxemia (68), direct effects ofparticles or
their reaction products on myocardial cells
(69), and cardiac consequences of airway
inflammation or injury (70,71). Recent
studies in healthy and compromised animals
from the laboratories of the U.S.
Environmental Protection Agency (69) and
from Harvard University (Boston, MA) (72)
have suggested that inhalation ofparticulate
pollutants may induce changes in cardiac
rhythm or repolarization. Pope and co-work-
ers (68) used pulse oximetry to study panels
ofelderly subjects residing at elevation. They
found no changes in oxygen saturation, but
there were small but significant increases in
heart rate associated with outdoor particle
concentrations. A 100-pg/m3 increase in the
previous-day level ofparticulate matter < 10
pm in diameter (PM1O) was associated with a
95% increase in the odds of a 10-beat
increase in the heart rate. These observations
have intensified efforts to understand the rela-
tionship between pollutant exposure and
changes in cardiac function.
One tool being used in this effort is
continuous cardiac monitoring, or Holter
recording. Originally used to identify silent
arrhythmias in cardiac patients, cardiac moni-
toring has revealed that both the pattern of
variation in heart rate, or heart ratevariability,
and the pattern ofelectrical repolarization of
the heart are markers ofcardiac health or dis-
ease. Decreased heart rate variability as well as
abnormalities in the duration, dynamics, and
heterogeneity ofrepolarization are established
noninvasive predictors ofarrhythmic events in
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patients with cardiovascular diseases (73-77)
and in healthy subjects (78). Dispersion of
repolarization, a noninvasive electrocardio-
graphic (EKG) measure ofspatial heterogene-
ity ofrepolarization, was increased in patients
with COPD (79), but also in healthy subjects
in response to hypoxemia (80).
These observations suggest that detailed
analyses ofthe continuous ambulatory EKG
for specific parameters, including heart rate
variability and repolarization, might provide
insights into the nature ofthe cardiac effects
ofpollutant exposure.
Pharmacokinetics ofInhaledVapors
Although inhaled chemicals such as NO2, 03,
and SO2 may cause direct damage to airway
and lung tissue, other vapors diffuse very
rapidly from the alveolar spaces, through the
lung tissue, and into blood, causing no direct
lung injury. CO diffuses into the blood and
binds avidly to hemoglobin. Other volatile
chemicals are absorbed by inhalation and sub-
sequently cause toxicity at sites distal to the res-
piratory tract. In addition, with some ofthese
chemicals, it is not theparentcompound thatis
most toxic but the metabolites, which may be
more reactive andmoredamagingtothetissue.
The ultimate objective ofmany toxicologic
studies is to take results from animal studies
and attempt to predict or describe expected
human responses. Physiologically based phar-
macokinetic (PBPK) models are used in an
attempt to describe the overall disposition of
an inhaled chemical by simulating the uptake,
distribution, metabolism, and elimination of
the inhaled material (81). The PBPK model is
then used in extrapolation between species
based on animal scaling techniques. The ade-
quacy ofinterspecies models should be tested
by extrapolating the results ofexperiments
with animal models to humans and comparing
them with the relatively limited data available
from controlledhuman exposures.
Although the strengths and limitations of
the PBPK approach are beyond the scope of
this article, Gargas and Andersen (81) previ-
ously reviewed the necessary parameters
required to develop such models as well as the
application to several chemicals. Such models
have been developed for styrene (82) compar-
ing data for rats and humans. The extrapo-
lated model performed very well, predicting
the concentration profile in humans exposed
to 80 ppm styrene. Utell and co-workers (83)
examined the pharmacokinetics of cyclic
siloxanes in quantitative controlled exposure
studies. Silicones are commonlyfound in per-
sonal care products including antiperspirants
and hair sprays, with potential for exposure
by the respiratory route. Octamethlycyclo-
tetrasiloxane (D4), a volatile siloxane, is a
major silicone component ofthese consumer
products and as many as 200 million
Americans are exposed to D4 in personal care
products on adailybasis.
In these studies, 12 healthy subjects
inhaled 10 ppm D4 (122 pg/L) or air (con-
trol) during a 1-hr exposure via a mouthpiece.
Inspiratory and expiratory D4 levels were con-
tinuously measured as well as exhaled air and
plasma levels before, during, and after expo-
sure. Mean D4 intake was 137 mg, with a
mean uptake of 13 mg (intake x deposition
fraction). The mean deposition fraction at rest
was 13% and with exercise it fell to 7%.
Plasma measurements of D4 gave a mean
peak value of79 ng/g and indicated a rapid
nonlinear blood dearance. These types ofdata
regarding the mean D4 deposition fraction
anduptake areapplicable to estimates ofexpo-
sure from both consumer product use and
occupational exposure to D4 vapor.
Subsequent studies using 14C-labeled D4
should allow even better quantitative assess-
ments and detection ofmetabolites in blood
and urine. Comparison with data from ongo-
ing animal studies (84,85) will allow develop-
ment of PBPK models for extrapolation to
humans. The data from controlled human
studies should contribute in a meaningful way
to the riskassessment process.
Studying Susceptible Subjects
The concept ofsusceptibility is highly relevant
to public health protection and to the deliv-
ery ofhealth care. The United States Clean
Air Act (86) mandated that national ambient
air quality standards be established to protect
the health ofall susceptible groups within the
population.
There is a high degree ofvariability in
human responses to environmental agents. For
example, decrements in FEV1 following 4-hr
exposures to 0.22 ppm 03 varied from 0 to
more than 50% (Figure 1) (16), and yet the
determinants of this variability are largely
unknown. Some ofthe known and postulated
factors influencing variability in human
responses to pollutants are as follows: age, gen-
der, body size, exercise, pre-existing disease,
atopy, infection, airway geometry, smoking,
pregnancy, exposure history, airways respon-
siveness, nutritional status, antioxidantvitamin
intake, and antioxidant enzyme expression.
Variability isgenerallyincreased in populations
with respiratory disease, especially asthma.
Someoftheobservedvariabilitymaybe related
to the actual dose delivered to the lung epithe-
lium or to the distribution ofthe inhaled pol-
lutant. For example, retention ofinsoluble
2 pm particles was increased 50% in subjects
with COPD compared with healthy subjects,
and the increased deposition correlated with
the severity ofobstruction (87). The diversity
ofhuman responses and responsiveness must
be considered in designing and conducting
human clinical studies ofpollutant effects, and
careful attention must be given to subject
selection andcharacterization.
The concept ofsusceptibility is often over-
simplified by both researchers and regulators.
Rather than a single characteristic ofa given
population, susceptibility varies by pollutant
and by the health effect being considered.
There may be multiple health effects ofpollu-
tant exposure (i.e., symptoms, lung function
decrements, airway inflammation, infection,
cardiac effects, etc.), with a number ofsuscep-
tible populations for which mechanisms and
susceptibility factors differ. Susceptibility for a
given health effect may not confer susceptibil-
ity to a different health effect. A striking
example is exposure to O3: individuals who
experience the greatest reductions in lung
function are not necessarily more likely to
experience airway inflammatory effects
(19,35). Furthermore, the mechanisms by
which pollutant exposure contributes to respi-
ratory mortality may differ from those respon-
sible forexcess cardiovascular mortality.
An understanding ofthe mechanisms by
which ambient concentrations ofpollutants
increase mortality will require human clinical
studies ofsusceptible subjects. However, such
studies are limited by the special needs and
changing health status of the subjects.
Increased variability in measured parameters
often requires that studies ofsusceptible sub-
jects have larger numbers of subjects per
study group compared with studies ofhealthy
subjects. Medication use may alter responses
in some subjects. Measures must be taken to
protect the safety ofsusceptible subjects, who
may be more vulnerable to adverse effects or
complications from testing procedures or
pollutant exposures.
In this section we focus on the increased
susceptibility conferred by three chronic
conditions: asthma, COPD, and cardio-
vascular disease.
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Figure 1. Percent change in FEV, during and after
exposure to 0.22 ppm ozone, with intermittent exer-
cise, in healthy nonsmoking subjects who were either
nonresponsive (change in FEV, < 5%; *) or responsive
(change in FEV, > 15%; a) to ozone. Data from Torres
etal. (19).
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Asthma
In clinical studies, asthmatics exhibit exagger-
ated lung function responses to SO2, acidic
aerosols, and in some studies, NO2 and 03.
Asthmatics may also experience an enhanced
airwayinflammatory response to 03.
In the laboratory, the most striking effect
ofacute exposure to SO2 at concentrations of
1.0 ppm or below is the induction of
bronchoconstriction in asthmatics after expo-
sures lasting only 5 min (88). In contrast,
inhalation ofconcentrations in excess of 5.0
ppm causes only small decrements in airway
function in normal subjects. Similarly, clini-
cal studies have identified exercising adoles-
cent asthmatics (89) and adult asthmatics
(90) as susceptible to sulfuric acid aerosols at
high ambient concentrations, levels that do
not affect healthy volunteers. Although sev-
eral controlled human studies have found
asthmatics responsive to low levels ofNO2,
the findings have not been consistent (91).
The conflicting results among these studies
are probably related to differences in subject
selection and exposure protocols.
A number ofepidemiologic studies have
suggested that emergency room and hospital
visits for asthma are increased on high-03
days. It is therefore surprising that most con-
trolled clinical studies generally have not
found striking differences in lung function
responses to 03 in asthmatic compared with
healthy subjects. Several possible explanations
exist. In contrast to studies with healthy vol-
unteers, fewstudies ofasthmatic subjects have
been performed usingprolonged exposures or
repeated daily exposures. Furthermore, few
studies with asthmatic subjects have incorpo-
rated multiple periods ofmoderate-to-intense
exercise, a factor that contributes to changes
in airway function with low-level 03
exposure in healthyvolunteers.
One study has addressed some ofthese
issues. Horstman and colleagues (92) exposed
17 subjects with clinically active asthma and
13 healthy subjects to 0.16 ppm 03 for
7.6 hr, with multiple prolonged periods of
mild exercise. As shown in Table 2, asthmatic
subjects hadsignificantly larger decrements in
FEV1 and in FEV1/FVC, despite occasional
use ofbronchodilators before and during the
exposure. This study suggests that people
with clinically active asthma may be at
increased risk for bronchoconstriction follow-
ing prolonged exposures to environmentally
relevant concentrations of03.
Two recent studies suggested that mild
asthmatics may experience a neutrophilic air-
way inflammatory response to 03 exposure
that is more intense than in healthy subjects
(22,93). Recent studies have also shown that,
in asthmatics, 03 exposures at concentra-
tions sufficient to induce an airway inflam-
matory response increase responsiveness to a
subsequent allergen challenge (94). Clinical
investigations therefore suggest that the
mechanisms for exacerbation ofasthma fol-
lowing 03 exposure indude bronchoconstric-
tion, worsening ofairway inflammation, and
increased responsiveness to allergen challenge.
Asthmatics may also be more sensitive to
combinations ofpollutants. Frampton et al.
(95) examined the effects ofprior exposure to
low-level sulfuric acid aerosol on the airway
response to 03 in healthy and asthmatic sub-
jects. Exposure-response relationships were
examined using three levels of03, 0.08, 0.12,
and 0.18 ppm. The exposures were preceded
24 hr earlier by exposure to 100 pg/m3
H2S04 or NaCl aerosol. The acidic aerosol
and oxidant exposures were 3 hr in duration.
Thirty healthy and 30 allergic asthmatics
were studied. The findings revealed an inter-
active relationship between the 03 exposure
concentration and H2S04 or NaCI aerosol
preexposure in asthmatics but not in healthy
subjects. For the asthmatic subjects, 03
concentration-related differences in lung
function were observed with H2S04 preexpo-
sure but not with NaCl preexposure. These
effects were observed for both FVC andFEV,
immediately and 4 hr after 03 exposure.
These data suggest that preexposure to
H2S04 aerosols may alter responses to 03 in
exercisingasthmatics.
ChronicObstructiv PulmonaryDisease
Effects ofinhaled pollutants in COPD have
not been extensively examined. Patients with
COPD demonstrated similar or decreased lung
function responsiveness to 03 at levels up to
0.30 ppm compared with healthy nonsmokers
ofcomparable ages (96). To determine iflow-
level NO2 induces changes in pulmonary func-
tion, Morrow et al. (97) investigated responses
to inhalation of0.3 ppm NO2 for 4 hr in 20
COPD subjects with a mean age of60 years,
and all with a history ofcigarette smoking.
These subjects were compared with 20 elderly
healthysubjects. Criteria for indusion included
dyspnea on exertion, airways obstruction
[FEV1/FVC = 0.58 ± 0.09 (SD)] and a lack of
response to inhaled bronchodilators. During
intermittent light exercise breathing NO2,
COPD subjects demonstrated progressive
decrements from baseline in FVC and FEV,
and no changewith air. Subgroup analyses sug-
gested that responsiveness to NO2 decreased
withincreasedseverityofthe COPD.
CardiovascularDisease
Studies oflow-level exposure to CO have
focused on subpopulations with ischemic
heart disease and peripheral vascular disease.
In patients with exertional angina, early onset
of angina pectoris and depression of the
ST-segment on the electrocardiogram (a
marker ofmyocardial ischemia) have been
consistently observed at carboxyhemoglobin
(COHb) levels of2-4% by several investiga-
tive teams. In the largest ofthese studies, the
Health Effects Institute Multicenter CO
Study (98), 5 and 12% decreases in the time
to onset of ST-segment depression were
observed at COHb levels of 2 and 4%,
respectively. Significant decreases in time to
onset of angina were also demonstrated at
these COHb levels. These end points are
remarkably consistent and are compatible
with the hypothesis that an elevated COHb
level impairs the response ofthe myocardium
to increased metabolic demands.
New Experimental Approaches
ConcentatedAmbientAirPartides
Ambient air contains a complex mixture of
particles and gases containing a variety of
chemicals at trace levels that may interact in
causing health effects. A technology recently
developed allows fine particles in the air to be
concentrated in real time. Air is drawn
through a series ofvirtual impactors designed
so that particles less than 2.5 ,um in aerody-
namic diameter are progressively concen-
trated up to 25- to 30-fold (99). Ambient
gases, and particles in the ultrafine size range
(< 100 nm diameter) are not concentrated
using this methodology.
This instrument has been used to demon-
strate effects ofambient particulate matter in
animals. For example, Gordon and col-
leagues (100) exposed rats to concentrated
ambient air particles (CAPs) or filtered air
for 3 hr, and found a significant but transient
increase in circulating PMNs along with
small alterations in heart rate associated with
CAPs exposure. Godleski and colleagues (72)
exposed 12 dogs, 6 ofwhich had surgically
placed devices to induce transient coronary
occlusions, to CAPs or filtered air on multi-
ple occasions. In the 6 surgically treated
dogs, exposure to CAPs was associated with a
shortened time to ST elevation and an
increased magnitude ofST elevation during
Table2. Lung function changes following exposure to 0.16 ppm ozone for7.6 hr.a
Asthmatic Nonasthmatic
Air Ozone Air Ozone pb
FVCM% change) -0.3 ± 1.5 -12.2 ± 3.1 0.5 ± 0.9 -8.3 ± 1.8 0.33
FEV1 (% change) 2.7 ±3.0 -16.7 ± 4.2 1.2 ± 0.8 -8.6 ± 1.9 0.04
FEV1/FVC(%) 2± 1 -4±2 0±1 -1±1 0.02
"All values represent postexposure minus preexposure, means ± SE. hp-value: asthmatic vs nonasthmatic. Data from Horstman etal.(92).
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coronary occlusion. The implications of
these studies for human health remain
unclear, and human studies using CAPs are
now in progress (101,102).
The key strength ofthis technology is the
ability to separate particle effects from gaseous
pollutant effects in the atmospheric mix.
However, there are several potential problems.
The actual exposure concentration and parti-
de composition mayvaryday to day and even
hour to hour, depending on changes in out-
door particle levels and sources during the
experiment. The limited ability to define the
chemistry ofthe CAPs, and the day-to-day
changes in particle composition, introduces an
additional element ofvariability into the
experimental design. In addition, the failure to
concentrate ambient ultrafine particles may
have significance. Animal exposure studies
suggest that ultrafine particles have increased
potential to induce an airway inflammatory
response when compared on an equal mass
basis with larger partides, perhaps because of
their greater number and surface area (103).
The relative absence ofultrafine particles and
gaseous pollutants must be considered when
interpreting the results ofCAPsstudies.
DieselEngineE ust
Another approach to the problem ofmixtures
is illustrated by recent studies ofexposure to
diesel exhaust. Diesel engines have gained
favor in may parts ofthe world because of
reduced operating costs and reduced emis-
sions ofCO, CO2, and hydrocarbons, com-
pared with gasoline engines. However, they
appear to release greater quantities offine and
ultrafine partides and nitrogen oxides (104).
Salvi et al. (30) exposedhealthysubjects for
1 hr to dilute exhaust from an operatingVolvo
diesel engine in a specially designed exposure
facility. Bronchoscopy with bronchoalveolar
lavage and bronchial biopsy were performed 6
hr after exposure. In comparison with control
air exposures, a significant increase was
observed in epithelial leukocytes and mast
cells, with increased expression ofthe adhesion
molecules ICAM-1 and VCAM-1 in submu-
cosal endothelium. Thus, diesel exhaust
induces airway inflammation in healthy sub-
jects in theabsenceofeffects onlungfunction.
Nasalchallenge with diesel exhaust particles
has been shown to enhance the local ragweed-
specific IgE response in subjects with allergic
rhinitis and to drive the nasal cytokine response
toward the Th2, or allergic phenotype (105).
These findings raise concerns about diesel
exhaust as a contributor to the increased preva-
lence ofallergicrhinitisandasthma.
"Smokinge' Machines
Using smoking machines, controlled expo-
sure studies have examined the role of envi-
ronmental tobacco smoke (ETS) in the
exacerbation ofasthma (106). Ofcourse, by
design, participants cannot be blinded to the
ETS exposure. Typically, briefexposure to
ETS produces symptoms such as eye and
nasopharyngeal irritation. Although there are
a few positive studies with ETS, the majority
document no significant effect on FEV1 or
measures ofairway responsiveness. However,
study design has not been optimal; limited
sample size, briefduration ofexposure, and
unrealistic exposure designs all emphasize the
need for careful protocol development ifthis
important clinical and social issue is to be
better understood.
ModelPartideEiposures
Studies of CAPs, diesel exhaust, and other
real-world particles are unable to determine
which particle characteristics, or combina-
tions ofcharacteristics, are responsible for the
observed effects. One approach to this prob-
lem is to use particles with specific size char-
acteristics or chemical composition to test
specific hypotheses. This approach permits
careful control ofthe particle to be tested,
and permits precise exposure-response assess-
ments. However, the particle design must be
guided by detailed chemical and size charac-
terization ofambient particles and by prelimi-
naryanimal exposure studies to assure safety.
Our laboratory is using this approach to
test the hypothesis that particles in the ultra-
fine size range have greater potential than
larger particles to induce airway inflamma-
tion, systemic acute phase responses, and
changes in cardiac repolarization. We have
developed and tested a facility that permits
exposures ofhumans to ultrafine particles of
varying composition and that also permits the
quantitative determination ofexposure levels,
respiratory intakes, and depositions ofthe
aerosol. Using this facility, we have initiated
clinical studies ofexposure to ultrafine parti-
cles in healthy human subjects at rest and
exercising (107).
Conclusions and Future
Directionsfor Human Studies
Controlled dinical studies provide a means for
examining responses to air pollutants and
chemical vapors, especially those identified
from epidemiologic studies. Well-characterized
exposures have been performed either in
environmental chambers or by mouthpiece
and the responses assessed primarily by respira-
tory mechanics or from direct sampling ofres-
piratory tract fluids, cells, and tissues. BAL
studies have demonstrated pollutant-induced
inflammation, lung injury, and decreased host
defense capacity. Less invasive techniques such
as nasal lavage and induced sputum also have
been used to show pollutant-induced inflam-
mation. Clinical studies have used a wide
range ofpotentially sensitive subpopulations
indudingasthmatics, children, the elderly, and
people with COPD and coronary artery dis-
ease. To date, clinical studies with air pollu-
tants have identified susceptible populations,
characterized exposure-response relationships,
and examined lowest-effect levels. With recent
epidemiologic observations linking elevated
partide concentrations with adverse cardiovas-
cular events, clinical studies will focus on
markers ofsystemic effects and changes in car-
diac function linked with acute cardiac events.
The introduction ofthe particle concentrator
should strengthen the ability ofclinical studies
tostudyreal ambient mixtures.
A variety ofopportunities exist for exten-
sion of clinical studies into new arenas.
Zelikoffet al. (29) examined effects ofH2S04
aerosol exposures, comparing responses in a
laboratory animal model commonly used for
toxicologic assessment with those observed in
human volunteers. The purpose ofthis collab-
orative study was to provide a basis for extrap-
olation offindings in animals to humans.
Substantial concordance between humans and
rabbits was found with regard to the cells
recovered in BAL fluid, and alveolar
macrophage immuno-responsiveness, in rela-
tion to H2S04exposure. For example, in both
species, a single 2-hr inhalation exposure to
H2S04 aerosol failed to evoke an inflamma-
tory response, alter lavageable protein levels, or
produce changes in cell viability. The results of
directly comparative studies can provide data
necessaryfor riskassessment and forpredicting
the accuracyofextrapolation modeling.
Finally, there are unique opportunities to
combine the strengths ofclinical and epi-
demiologic studies in the effort to understand
mechanisms ofsusceptibility to pollutant
effects. Hackney et al. (108) recognized the
usefulness ofthis approach, and in avery lim-
ited study, found that four healthy subjects
residing in Canada showed greater decre-
ments in FEV1 following laboratory expo-
sures to 03 than did four residents of
southern California. This was considered to
be evidence that chronic exposure to 03 in
California blunted responsiveness in those
subjects, although the number ofsubjects was
too small to derive anydefinite conclusions.
A parallel approach may prove useful in
determining the mechanisms involved in
responses to particle exposure. For example,
groups ofsubjects identified from an epidemi-
ology or panel study as susceptible (symp-
toms, lung function, medication use, heart
rate variability, etc.) or nonsusceptible to par-
ticle effects could be studied in the laboratory
under controlled conditions, either to con-
centrated ambient particles or to a model par-
ticle. Conversely, groups of individuals
determined to be responders in a clinical
study could be followed in a panel study to
determine whether laboratory responses were
Environmental Health Perspectives * Vol 108, Supplement 4 * August 2000 611UTELL AND FRAMPTON
reproduced with actual ambient exposures.
These approaches will require a new level of
collaboration between investigators with
expertise in epidemiology and human clini-
cal studies but may provide key clues in our
understanding of the mechanisms for
susceptibility to pollutant effects.
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